← BioNTech
What podcasts say about BioNTech
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about BioNTech
3 statements · 1 positive · 2 negative
BioNTech and Roche’s neoantigen program has struggled to demonstrate clinical efficacy.
“that has really struggled to show efficacy in the clinic, including as monotherapy plus Keytruda.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 12:54
BioNTech and Roche’s Phase 3 trial failed its progression-free-survival endpoint.
“that failed to meet its progression-free survival endpoint.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 13:15
BioNTech is a good company or investment.
“I think you got a good one.”
Open the episode · Mad Money w/ Jim Cramer 8/26/26Listen at 36:04
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.